ISRCTN Registry (original) (raw)

Skip to content

BMC - Part of Springer Nature

ISRCTN registry The UK's Clinical Study Registry

ISRCTN registry The UK's Clinical Study Registry

BMC - Part of Springer Nature

ISRCTN registry The UK's Clinical Study Registry

ISRCTN registry

The ISRCTN registry is a primary clinical study registry recognised by the World Health Organisation (WHO) and the International Committee of Medical Journal Editors (ICMJE) that accepts all clinical research studies (whether proposed, ongoing or completed), providing content validation and curation and the unique identification number necessary for publication. All study records in the database are freely accessible and searchable.

ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base.

The registry aims to include all interventional and non-interventional clinical studies that prospectively involve UK participants and evaluate biomedical or health-related outcomes.

Studies conducted outside the UK or considered to be non-clinical studies (e.g. public health studies) can be registered on ISRCTN.

Studies should ideally be registered prospectively (before recruitment starts). ISRCTN also accepts studies registered retrospectively once they are underway or after completion.

Register your study Update your record Report your results

Latest studies

Overall study status
Ongoing
Recruitment status
Recruiting
Assessment of glucose levels and insulin requirements during the menstrual cycle in women using Medtronic 780G
Registration date
18/11/2024

Overall study status
Ongoing
Recruitment status
No longer recruiting
A cluster-randomised controlled feasibility trial of a Positive Early Childhood Education (PECE) CPD programme for educators to improve social and emotional outcomes for children in Early Years Settings.
Registration date
18/11/2024

Overall study status
Ongoing
Recruitment status
Not yet recruiting
Treatment of severe Diabetic macular oedema with Anti-vascular endothelial growth factor (anti-VEGF) monotherapy versus treatment with anti-VEGF followed by subthreshold Micropulse lasEr when the thickness of the central retina goes below 400 microns: a pragmatic randomised equivalence trial
Registration date
18/11/2024

Supporter organisations

Browse Studies

Springer Nature